Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Luisrojasstock/iStock via Getty Images Galectin Therapeutics (NASDAQ:GALT) has a major milestone approaching towards the end of 2024, which is going to be the release of data from the phase 2b NAVIGATE study. This particular study is exploring the use of Belapectin for the prevention of esophageal varices in patients with NASH cirrhosis. I believe that investors should focus on this biotech, because it is gearing up to report topline results from the phase 2b/3 NAVIGATE study in Q4 of 2024. This is goin ...